Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1201 participants.
Also called NCT02648204
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,201 participants
- Sponsor
- Registry
-
NCT02648204 -
2014-005375-91
-
- Main results
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Croatia, Finland, Germany, Greece, Hong Kong SAR China, India, Ireland, Latvia, Lithuania, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02648204. Randomized; no masking; primary purpose treatment. Start 2016-01-06 (actual); primary completion 2017-04-10 (actual). Results posted on 2018-05-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
- Acronym
- SUSTAIN 7
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02648204- Content hash
7aefaaed1ecdfe44f79c138cd40c586be238aa63db91b1a2434689b5d17bddde